by Nathaniel Harding | Mar 11, 2024 | Blog
Cortado Ventures is thrilled to have recently invested in Cadenza Bio, an Oklahoma life sciences company developing novel therapeutic drugs to treat demyelinating, inflammatory, and neurodegenerative diseases, with a first indication in multiple sclerosis (MS). Read...
by Nathaniel Harding | Mar 5, 2024 | Media
At Cortado Ventures, we are proud to be recognized by Forbes for our commitment to supporting diversity in entrepreneurship. In a recent feature by Forbes contributor Soulaima Gourani, our efforts to empower minority entrepreneurs were highlighted, showcasing our...
by Nathaniel Harding | Feb 22, 2024 | Media
As part of the relentless pursuit to redefine the boundaries of Earth observation, Nuview announced its acquisition of Astraea, a leading spatial intelligence platform. This strategic move marks a significant milestone in their journey to revolutionize the Earth...
by Nathaniel Harding | Feb 22, 2024 | Media
Nathan Den Herder, CEO and Founder of Ardley sits down for an exclusive interview to discuss the launch of their cutting-edge autopilot underwriting engine. Featured in top publications, including Housingwire, Mortgage Bankers Association, National Mortgage News and...
by Nathaniel Harding | Feb 22, 2024 | Blog
A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad Cortado is thrilled to invest in CorriXR Therapeutics, an early-stage biotech company commercializing a platform gene editing technology with a first-use case in oncology. The novel approach seeks to...
